Exact Mass: 506.3355696

Exact Mass Matches: 506.3355696

Found 75 metabolites which its exact mass value is equals to given mass value 506.3355696, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Chenodeoxycholylasparagine

3-carbamoyl-2-(4-{5,9-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl}pentanamido)propanoic acid

C28H46N2O6 (506.3355696)


Chenodeoxycholylasparagine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Chenodeoxycholylasparagine consists of the bile acid chenodeoxycholic acid conjugated to the amino acid Asparagine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Chenodeoxycholylasparagine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Chenodeoxycholylasparagine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).

   

Deoxycholylasparagine

2-[(4-{5,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0,.0,]heptadecan-14-yl}-1-hydroxypentylidene)amino]-3-(C-hydroxycarbonimidoyl)propanoate

C28H46N2O6 (506.3355696)


Deoxycholylasparagine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Deoxycholylasparagine consists of the bile acid deoxycholic acid conjugated to the amino acid Asparagine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Deoxycholylasparagine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Deoxycholylasparagine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).

   

Anadur

(13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl) 3-(4-hexoxyphenyl)propanoate

C33H46O4 (506.3395916)


   
   

amphimedoside A|N-methoxy-N-(16-pyridin-3-ylhexadec-11-yn-1-yl)-beta-D-glucopyranosylamine

amphimedoside A|N-methoxy-N-(16-pyridin-3-ylhexadec-11-yn-1-yl)-beta-D-glucopyranosylamine

C28H46N2O6 (506.3355696)


   

(2S,1R,2R,4S)-fenchyl-3,4-dihydro-5-hydroxy-2,7-dimethyl-8-(3-methyl-2-butenyl)-2-(4-methyl-1,3-pentadienyl)-2H-1-benzopyran-6-carboxylate

(2S,1R,2R,4S)-fenchyl-3,4-dihydro-5-hydroxy-2,7-dimethyl-8-(3-methyl-2-butenyl)-2-(4-methyl-1,3-pentadienyl)-2H-1-benzopyran-6-carboxylate

C33H46O4 (506.3395916)


   

(2R,1S,2R,4S)-bornyl-3,4-dihydro-5-hydroxy-2,7-dimethyl-8-(3-methyl-2-butenyl)-2-(4-methyl-1,3-pentadienyl)-2H-1-benzopyran-6-carboxylate

(2R,1S,2R,4S)-bornyl-3,4-dihydro-5-hydroxy-2,7-dimethyl-8-(3-methyl-2-butenyl)-2-(4-methyl-1,3-pentadienyl)-2H-1-benzopyran-6-carboxylate

C33H46O4 (506.3395916)


   

19-hydroxy-18-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosanoic acid

NCGC00384950-01!19-hydroxy-18-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosanoic acid

C26H50O9 (506.345465)


   

Asparagine conjugated chenodeoxycholic acid

Asparagine conjugated chenodeoxycholic acid

C28H46N2O6 (506.3355696)


   

((4R)-4-((3R,5R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)glycylglycine

"((4R)-4-((3R,5R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)glycylglycine"

C28H46N2O6 (506.3355696)


   

[2-(hexanoyloxymethyl)-2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-3-propoxypropyl] heptanoate

[2-(hexanoyloxymethyl)-2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-3-propoxypropyl] heptanoate

C26H50O9 (506.345465)


   

Cholan-24-oic acid,6-ethylidene-3-hydroxy-7-oxo-,phenylmethyl ester, (3α,5β)-

Cholan-24-oic acid,6-ethylidene-3-hydroxy-7-oxo-,phenylmethyl ester, (3α,5β)-

C33H46O4 (506.3395916)


   

19-Nortestosterone 4-hexyloxyphenylpropionate

19-Nortestosterone 4-hexyloxyphenylpropionate

C33H46O4 (506.3395916)


   

Deoxycholylasparagine

Deoxycholylasparagine

C28H46N2O6 (506.3355696)


   
   
   

Mgdg O-13:0_4:0

Mgdg O-13:0_4:0

C26H50O9 (506.345465)


   

Mgdg O-15:0_2:0

Mgdg O-15:0_2:0

C26H50O9 (506.345465)


   

Mgdg O-11:0_6:0

Mgdg O-11:0_6:0

C26H50O9 (506.345465)


   

Mgdg O-14:0_3:0

Mgdg O-14:0_3:0

C26H50O9 (506.345465)


   

Mgdg O-10:0_7:0

Mgdg O-10:0_7:0

C26H50O9 (506.345465)


   

Mgdg O-12:0_5:0

Mgdg O-12:0_5:0

C26H50O9 (506.345465)


   

19-Hydroxy-18-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosanoic acid

19-Hydroxy-18-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosanoic acid

C26H50O9 (506.345465)


   

((4R)-4-((3R,5R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)glycylglycine

((4R)-4-((3R,5R,9S,10S,12S,13R,14S,17R)-3,12-dihydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoyl)glycylglycine

C28H46N2O6 (506.3355696)


   

FAHFA 10:2/O-23:7

FAHFA 10:2/O-23:7

C33H46O4 (506.3395916)


   

FAHFA 10:3/O-23:6

FAHFA 10:3/O-23:6

C33H46O4 (506.3395916)


   

FAHFA 11:2/O-22:7

FAHFA 11:2/O-22:7

C33H46O4 (506.3395916)


   

FAHFA 11:3/O-22:6

FAHFA 11:3/O-22:6

C33H46O4 (506.3395916)


   

FAHFA 12:2/O-21:7

FAHFA 12:2/O-21:7

C33H46O4 (506.3395916)


   

FAHFA 12:3/O-21:6

FAHFA 12:3/O-21:6

C33H46O4 (506.3395916)


   

FAHFA 12:4/O-21:5

FAHFA 12:4/O-21:5

C33H46O4 (506.3395916)


   

FAHFA 13:3/O-20:6

FAHFA 13:3/O-20:6

C33H46O4 (506.3395916)


   

FAHFA 13:4/O-20:5

FAHFA 13:4/O-20:5

C33H46O4 (506.3395916)


   

FAHFA 14:3/O-19:6

FAHFA 14:3/O-19:6

C33H46O4 (506.3395916)


   

FAHFA 14:4/O-19:5

FAHFA 14:4/O-19:5

C33H46O4 (506.3395916)


   

FAHFA 15:3/O-18:6

FAHFA 15:3/O-18:6

C33H46O4 (506.3395916)


   

FAHFA 15:4/O-18:5

FAHFA 15:4/O-18:5

C33H46O4 (506.3395916)


   

FAHFA 15:5/O-18:4

FAHFA 15:5/O-18:4

C33H46O4 (506.3395916)


   

FAHFA 16:4/O-17:5

FAHFA 16:4/O-17:5

C33H46O4 (506.3395916)


   

FAHFA 16:5/O-17:4

FAHFA 16:5/O-17:4

C33H46O4 (506.3395916)


   

FAHFA 17:4/O-16:5

FAHFA 17:4/O-16:5

C33H46O4 (506.3395916)


   

FAHFA 17:5/O-16:4

FAHFA 17:5/O-16:4

C33H46O4 (506.3395916)


   

FAHFA 18:4/O-15:5

FAHFA 18:4/O-15:5

C33H46O4 (506.3395916)


   

FAHFA 18:5/O-15:4

FAHFA 18:5/O-15:4

C33H46O4 (506.3395916)


   

FAHFA 18:6/O-15:3

FAHFA 18:6/O-15:3

C33H46O4 (506.3395916)


   

FAHFA 19:5/O-14:4

FAHFA 19:5/O-14:4

C33H46O4 (506.3395916)


   

FAHFA 19:6/O-14:3

FAHFA 19:6/O-14:3

C33H46O4 (506.3395916)


   

FAHFA 20:5/O-13:4

FAHFA 20:5/O-13:4

C33H46O4 (506.3395916)


   

FAHFA 20:6/O-13:3

FAHFA 20:6/O-13:3

C33H46O4 (506.3395916)


   

FAHFA 21:5/O-12:4

FAHFA 21:5/O-12:4

C33H46O4 (506.3395916)


   

FAHFA 21:6/O-12:3

FAHFA 21:6/O-12:3

C33H46O4 (506.3395916)


   

FAHFA 21:7/O-12:2

FAHFA 21:7/O-12:2

C33H46O4 (506.3395916)


   

FAHFA 22:6/O-11:3

FAHFA 22:6/O-11:3

C33H46O4 (506.3395916)


   

FAHFA 22:7/O-11:2

FAHFA 22:7/O-11:2

C33H46O4 (506.3395916)


   

FAHFA 23:6/O-10:3

FAHFA 23:6/O-10:3

C33H46O4 (506.3395916)


   

FAHFA 23:7/O-10:2

FAHFA 23:7/O-10:2

C33H46O4 (506.3395916)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

2-methoxyphenyl 3-[4a,6-dimethyl-5-(3-methylpentyl)-octahydro-1h-naphthalen-1-yl]-2-methoxybenzoate

2-methoxyphenyl 3-[4a,6-dimethyl-5-(3-methylpentyl)-octahydro-1h-naphthalen-1-yl]-2-methoxybenzoate

C33H46O4 (506.3395916)


   

4-{[(4e,7e)-1-(3-hexyl-4-oxooxetan-2-yl)trideca-4,7-dien-2-yl]oxy}-3-[(1-hydroxyethylidene)amino]-4-oxobutanimidic acid

4-{[(4e,7e)-1-(3-hexyl-4-oxooxetan-2-yl)trideca-4,7-dien-2-yl]oxy}-3-[(1-hydroxyethylidene)amino]-4-oxobutanimidic acid

C28H46N2O6 (506.3355696)


   

(3s)-4-{[(2r,4e,7e)-1-[(2r,3r)-3-hexyl-4-oxooxetan-2-yl]trideca-4,7-dien-2-yl]oxy}-3-[(1-hydroxyethylidene)amino]-4-oxobutanimidic acid

(3s)-4-{[(2r,4e,7e)-1-[(2r,3r)-3-hexyl-4-oxooxetan-2-yl]trideca-4,7-dien-2-yl]oxy}-3-[(1-hydroxyethylidene)amino]-4-oxobutanimidic acid

C28H46N2O6 (506.3355696)


   

2-methoxyphenyl 3-[(1s,4ar,5s,6s,8as)-4a,6-dimethyl-5-[(3r)-3-methylpentyl]-octahydro-1h-naphthalen-1-yl]-2-methoxybenzoate

2-methoxyphenyl 3-[(1s,4ar,5s,6s,8as)-4a,6-dimethyl-5-[(3r)-3-methylpentyl]-octahydro-1h-naphthalen-1-yl]-2-methoxybenzoate

C33H46O4 (506.3395916)